Annual Current Assets
$438.14 M
-$131.68 M-23.11%
December 31, 2023
Summary
- As of February 12, 2025, RXRX annual total current assets is $438.14 million, with the most recent change of -$131.68 million (-23.11%) on December 31, 2023.
- During the last 3 years, RXRX annual current assets has risen by +$171.70 million (+64.44%).
- RXRX annual current assets is now -23.11% below its all-time high of $569.81 million, reached on December 31, 2022.
Performance
RXRX Current Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Assets
$474.17 M
-$48.20 M-9.23%
September 30, 2024
Summary
- As of February 12, 2025, RXRX quarterly total current assets is $474.17 million, with the most recent change of -$48.20 million (-9.23%) on September 30, 2024.
- Over the past year, RXRX quarterly current assets has increased by +$130.56 million (+38.00%).
- RXRX quarterly current assets is now -26.78% below its all-time high of $647.63 million, reached on June 30, 2021.
Performance
RXRX Quarterly Current Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Assets Formula
Current Assets = Cash and Equivalents + Accounts Receivable + Inventory + Prepaid Expenses + Marketable Securities + Other Current Assets
RXRX Current Assets Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -23.1% | +38.0% |
| 3 y3 years | +64.4% | -16.8% |
| 5 y5 years | +473.5% | -16.8% |
RXRX Current Assets Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -23.1% | at low | -23.4% | +38.0% |
| 5 y | 5-year | -23.1% | +473.5% | -26.8% | +113.8% |
| alltime | all time | -23.1% | +473.5% | -26.8% | +113.8% |
Recursion Pharmaceuticals Current Assets History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $474.17 M(-9.2%) |
| Jun 2024 | - | $522.38 M(+52.0%) |
| Mar 2024 | - | $343.62 M(-21.6%) |
| Dec 2023 | $215.56 M(+64.0%) | $438.14 M(+6.7%) |
| Sep 2023 | - | $410.52 M(-4.8%) |
| Jun 2023 | - | $431.02 M(-12.4%) |
| Mar 2023 | - | $492.13 M(-13.6%) |
| Dec 2022 | $131.47 M | $569.81 M(+18.3%) |
| Sep 2022 | - | $481.62 M(-11.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $546.00 M(-11.9%) |
| Mar 2022 | - | $619.46 M(+15.8%) |
| Dec 2021 | $75.63 M(+135.2%) | $534.72 M(-11.0%) |
| Sep 2021 | - | $600.87 M(-7.2%) |
| Jun 2021 | - | $647.63 M(+192.0%) |
| Mar 2021 | - | $221.82 M(-16.7%) |
| Dec 2020 | $32.15 M(+28.4%) | - |
| Dec 2020 | - | $266.44 M |
| Dec 2019 | $25.03 M | - |
FAQ
- What is Recursion Pharmaceuticals annual total current assets?
- What is the all time high annual current assets for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual current assets year-on-year change?
- What is Recursion Pharmaceuticals quarterly total current assets?
- What is the all time high quarterly current assets for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly current assets year-on-year change?
What is Recursion Pharmaceuticals annual total current assets?
The current annual current assets of RXRX is $438.14 M
What is the all time high annual current assets for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual total current assets is $569.81 M
What is Recursion Pharmaceuticals annual current assets year-on-year change?
Over the past year, RXRX annual total current assets has changed by -$131.68 M (-23.11%)
What is Recursion Pharmaceuticals quarterly total current assets?
The current quarterly current assets of RXRX is $474.17 M
What is the all time high quarterly current assets for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly total current assets is $647.63 M
What is Recursion Pharmaceuticals quarterly current assets year-on-year change?
Over the past year, RXRX quarterly total current assets has changed by +$130.56 M (+38.00%)